








Take a moment to explore TRI’s history through our significant milestones. Since our establishment in 2013, we have been at the forefront of providing exceptional quality management solutions.
In 2013, TRI marked its entry into the world of clinical trial quality management by opening our first office in the historic and intellectually vibrant city of Cambridge. This milestone symbolized our commitment to innovation and excellence, setting the stage for a future where research and technology converge to redefine industry standards.
Our journey took a significant leap forward in 2016 with the launch of OPRA-CM, our centralized monitoring platform. Designed with precision and user experience in mind, OPRA-CM revolutionized how research data is monitored, ensuring higher quality, efficiency, and compliance in clinical trials. This innovation underscored our dedication to transforming research methodologies through smart technology.
In 2020, TRI once again pushed the boundaries of quality management by unveiling our advanced risk assessment and management tool, OPRA-RAM. This tool was developed to empower researchers to proactively identify, evaluate, and mitigate risks in their studies, ensuring the utmost integrity and reliability of research outcomes. This launch not only highlighted our ongoing commitment to safety and excellence but also set new benchmarks in research risk management.
In 2025, TRI announced a major overhaul of OPRA-CM, redefining centralized monitoring to deliver RBQM’s true promise. The reimagined platform cuts complexity and connects clinical and operational data in one view. It automates workflows and surfaces actionable risk insights. Clinical teams can improve oversight, make faster decisions, and reduce monitoring costs by up to 30%.
In 2026, TRI transformed study oversight with the launch of OPRA‑SM, our subject‑level monitoring solution designed for trials where every data point carries weight. By replacing fragmented spreadsheets with a unified, contextual view of the full patient journey, OPRA‑SM empowers teams to detect safety signals earlier, make clearer clinical decisions, and demonstrate stronger, audit‑ready oversight. This milestone reinforced TRI’s commitment to elevating research quality while protecting the patients at the heart of every study.
Dependable software. Genuine trust. TRI delivers, on time, at scale, with clarity.
In a rigid industry, we’re the human touch: pragmatic, responsive, and known by name.
We lead, not follow. TRI is fast-moving and data-informed, staying ahead of Sponsor and CRO needs.